| |
Patients with FeNO<37 ppb (n = 25) |
Patients with FeNO ≥ 37 ppb(n = 12) |
ANOVA |
| |
0W |
8W |
p-Value |
0W |
8W |
p-Value |
p-Value |
| ACQ5, overall score |
0.0(0.0-0.2) |
0.0(0.0-0.2) |
0.2341 |
0.0(0.0-0.1) |
0.0(0.0-0.0) |
1.0000 |
0.7678 |
| FVC, L |
3.02(2.43-3.44) |
3.12(2.45-3.58) |
0.6271 |
3.47(2.67-4.05) |
3.35(2.50-3.87) |
0.4769 |
0.6890 |
| %FVC, % |
97.9(88.0-109.6) |
98.1(86.7-109.8) |
0.5111 |
115.8(104.6-134.2) |
114.6(97.1-132.4) |
0.4236 |
0.7565 |
| FEV1, L |
2.36(1.80-2.91) |
2.29(1.72-2.79) |
0.0591 |
2.43(1.86-2.97) |
2.15(1.78-3.03) |
0.4145 |
0.8900 |
| %FEV1 (% predicted) |
88.2(80.6-105.1) |
85.9(76.9-104.8) |
0.0593 |
106.2(79.1-112.0) |
101.9(72.0-111.0) |
0.3329 |
0.7697 |
| %FEF50%, % |
64.0(47.8-102.9) |
63.3(46.1-98.0) |
0.1137 |
57.7(40.0-91.9) |
49.8(31.4-91.9) |
0.2477 |
0.8567 |
| %FEF75%, % |
46.5(34.8-81.1) |
44.3(25.7-75.5) |
0.0765 |
37.4(25.8-62.5) |
25.5(18.8-69.5) |
0.2845 |
0.8266 |
| PEF variability, % |
3.3(2.0-5.7) |
3.0(2.0-4.7) |
0.1440 |
2.7(1.8-4.6) |
2.9(1.4-5.9) |
0.2026 |
0.8770 |
| Min%Max PEF, % |
90.3(87.1-93.0) |
91.0(86.1-93.0) |
0.9405 |
90.0(87.8-94.8) |
91.5(86.1-95.6) |
0.4413 |
0.2957 |
| FeNO, ppb |
20.0(18.0-28.0) |
25.5(18.8-34.5) |
0.0495 |
51.5(40.8-57.5) |
67.0(33.0-76.0) |
0.2298 |
0.7565 |
Data are expressed as the medians (interquartile ranges).
Abbreviations: ACQ5: Asthma Control Questionnaire, 5-item version; ANOVA:Analysis Of Variance; FBC:Formoterol/Budenonide Combination; FEF50%:Forced Expiratory Flow at 50% of FVC; FeNO:Fractional Exhaled Nitric Oxide; FEV1:Forced Expiratory Volume in 1 Second; FVC:Forced Vital Capacity; Min%Max PEF:The Lowest PEF Over a Week Expressed as the Percentage of the Highest PEF; PEF:Peak Expiratory Flow.*p <0.05 versus 0 W. |
